A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Last Update: Aug 02, 2024
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
ClinicalTrials.gov Identifier:
Novartis Reference Number:CPI-0209-01
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2. Emerging evidence suggests that EZH2 is overexpressed in many cancer types and has a pivotal role in disease progression. This is a Phase 1/2, open-label, multi-center, FIH study designed to evaluate the safety and tolerability and preliminary clinical activity of CPI-0209, an EZH2/1 inhibitor as monotherapy in patients with advanced solid tumors and lymphomas. Phase 1 is composed of a CPI-0209 Dose Escalation period in patients with advanced tumors and aims to determine maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of CPI-0209 as monotherapy in patients with advanced tumors.

Phase 2 is planned to evaluate safety and tolerability and antitumor activity of CPI-0209 in six disease-specific cohorts (M1 to M6). Patients in Cohorts M1, M2, M3, M5, and M6 will be enrolled at 10 to 29 patients per cohort, using a Simon 2-stage design. Cohort M4 will enroll up to 20 patients with lymphoma in a single-stage. The primary aim of Phase 2 part of the study is to evaluate the antitumor activity of CPI-0209, and characterize the safety and tolerability of CPI-0209 as monotherapy in patients with selected tumors.

In Phase 2, two additional doses are planned to be evaluated in cohorts M2 and M3 in 2 stages: Stage 2a and Stage 2b. In Stage 2a approximately 20 patients will be enrolled per cohort and will be randomized 1:1 to receive 2 prespecified dose levels of CPI-0209 once daily. When protocol criteria for initiating Stage 2b will be fulfilled after completion of Stage 2a, then Stage 2b will be opened for enrolment of additional 10 patients in one or both dose arms in each of the two cohorts. Thus, up to 40 patients per cohort (M2 and M3) could be enrolled.

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
Phase1, Phase2
Recruiting
210
Sep 18, 2019
Mar 01, 2026
All
18 Years - (Adult, Older Adult)

Interventions

Drug

CPI-0209

CPI-0209 alone

Eligibility Criteria

Inclusion Criteria:

Phase 1

Eligible Phase 1 patients are adults who have a confirmed locally advanced or metastatic tumors (solid tumors or lymphoma) that have relapsed following standard therapy or progressed through standard therapy or who have a disease for which no standard effective therapy exists.

Phase 2:

* Life expectancy of ≥ 12 weeks
* ECOG 0-1
* Adequate bone marrow function
* Adequate renal function
* Adequate liver function

For Cohort M1, the following criteria should be considered:

* Histologically confirmed locally advanced unresectable or metastatic urothelial carcinoma with predominant urothelial histology
* • Histologically confirmed metastatic solid tumor (except ovarian clear cell cancer, endometrial cancer, and pleural or peritoneal mesothelioma)
* Known ARID1A mutation (NGS testing)
* Disease progression during or following prior chemotherapy approved therapies or for which no standard therapy exists
* Measurable disease per RECIST 1.1

For Cohort M2, the following criteria should be considered:

* Histologically confirmed advanced ovarian clear cell carcinoma
* Known ARID1A mutation (by NGS testing)
* Received at least 1 line of platinum-based chemotherapy and must have received bevacizumab as part of any line of treatments unless contraindicated or locally not approved or locally not accessible
* Measurable disease per RECIST 1.1
* Patient must have disease progression after previously receiving effective and available standard of care treatment for clear cell ovarian cancer per local clinical practice

For Cohort M3, the following criteria should be considered:

* Histologically or cytologically confirmed recurrent, metastatic, or unresectable endometrial carcinoma
* Known ARID1A mutation (by NGS testing)
* Received at least 1 line of platinum-based regimen in recurrent/metastatic setting
* Documented microsatellite instability (MSI)-high or deficient mismatch repair (dMMR) or patients who have non-dMMR/microsatellite stable tumors should have received an anti-PD-1 or anti-PD-L1 agent alone or in combination with the approved agents as applicable, as part of their prior treatments unless considered not eligible, contraindicated or if not locally approved
* Brachytherapy is allowed if completed \>12 weeks before the first dose of study drug
* Measurable disease per RECIST 1.1
* Patients must have previously received effective and available standard of care treatment options for endometrial cancer per local clinical practice unless these are contraindicated

For Cohort M4, the following criteria should be considered:

* PTCL or DLBCL with the following criteria:
* PTCL
* Documented refractory, relapsed, or progressive disease after at least 1 prior line of systemic therapy. Refractory is defined as:
* Failure to achieve CR after first-line therapy
* Failure to reach at least PR after second-line therapy or beyond
* Must have at least 1 prior line of systemic therapy for PTCL.
* Participants must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented.
* In the PTCL cohort, participants with anaplastic large cell lymphoma (ALCL) must have prior brentuximab vedotin treatment.
* DLBCL:
* Relapsed or refractory disease following 2 or more prior lines of standard therapy.
* Not considered candidates to receive CAR-T or autologous hematopoietic stem cell transplant (ASCT) as assessed by the treating investigator for reasons such as age, underlying comorbidities, performance status, or due to disease progression after previously received ASCT or CAR-T. The reason for transplant ineligibility must be clearly documented.
* For patients who underwent past ASCT or CAR-T treatment, at least 90 days must have elapsed since the start of the procedure. For all other patients, at least 8 weeks must have elapsed since their most recent systemic anti-DLBCL therapy

For Cohort M5, the following criteria should be considered:

* Pleural or peritoneal relapsed/refractory mesothelioma
* Must have progressed on or after at least 1 prior line of active therapy
* Measurable disease per modified RECIST 1.1 for pleural mesothelioma or by RECIST 1.1 for peritoneal mesothelioma
* Known BAP1 loss per immunohistochemistry (IHC) or NGS

For Cohort M6, the following criteria should be considered:

* Have measurable soft-tissue disease
* Documented metastatic disease
* Disease progression while on prior therapies
* Baseline testosterone ≤50 ng/dL (≤2.0 nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study

Exclusion Criteria

Medical Conditions

* Previous solid organ or allogeneic hematopoietic cell transplant (HCT)
* Known symptomatic untreated brain metastases
* Clinically significant cardiovascular disease
* Major surgery within 4 weeks before starting study drug or not recovered from any effects of prior major surgery
* Gastrointestinal disorders or any other condition that may significantly interfere with absorption of the study medication by Investigator's assessment.
* Uncontrolled active infection requiring intravenous antibiotic, antiviral, or antifungal medications within 14 days before the first dose of study drug. Infections (eg, urinary tract infection) controlled on concurrent antimicrobial agents and antimicrobial prophylaxis per institutional guidelines are acceptable.
* Suspected pneumonitis or interstitial lung disease or a history of pneumonitis or interstitial lung disease.
* Have a history of a concurrent or second malignancy. Patients with a history of T-cell lymphoblastic lymphoma or T-Cell lymphoblastic leukemia are not eligible.
* Have current known active or chronic infection with HIV, hepatitis B, or hepatitis C. Screening of patients with serologic testing for these viruses is not required
* Clinically active or symptomatic viral hepatitis or chronic liver disease.
* Unstable or severe uncontrolled medical condition or any important medical or psychiatric illness or abnormal laboratory finding
* Previous solid organ or allogeneic hematopoietic cell transplant HCT.

Prior/Concomitant Therapy:

* Prior anticancer treatment:

* Prior systemic anticancer treatment with chemotherapy, targeted therapy, small molecule, antibody, or investigational anticancer therapy (includes prior PD-1 or PD-L1 therapy), or other anticancer therapeutic with the exception of gonadotropin releasing hormone analogues, within 4 weeks (or 5 half-lives), whichever is shorter, before the first dose of study drug (6 weeks washout for nitrosoureas or mitomycin C).
* Previous treatment with an EZH2 inhibitor
* Prior radiation therapy within 4 weeks before first dose of study drug
* Prior stereotactic body radiation therapy within 2 weeks before first dose of study drug
* Prior chemoembolization or radioembolization within 4 weeks before first dose of study drug.
* Concomitant medication(s) or food or beverage that are strong CYP3A inducers or inhibitors within 7 days prior to the first dose of study drug.

Other Exclusions

• Breastfeeding or pregnant woman or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 183 days after the last dose of study drug.

Cohort M6 (mCRPC) only

* Bone-only disease without nodal disease and no evidence of visceral spread
* Structurally unstable bone lesions concerning for impending fracture
* Herbal products that may decrease prostate-specific antigen within 4 weeks prior to Day 1 of treatment and while on study
* Treatment for prostate cancer (First generation androgen receptor antagonists within 4 weeks; 5α-reductase inhibitors, ketoconazole, estrogens, or progesterones within 2 weeks)
* Planned palliative procedures such as radiation therapy or surgery

Oscar Lambret Center

Recruiting

Lille,59020,France

Cyril Abdeddaim
Solaya Chalal

Hospital North

Recruiting

Nantes,44093,France

Tiphaine Chiron
Thomas Gastinne
Thomas Gastinne, MD

Strasbourg Europe Institut of Cancerology

Recruiting

Strasbourg,23025,France

Lucie-Anne Casper
Lauriane Eberst

Gustave Roussy

Recruiting

Villejuif,94805,France

Vincent Ribrag, MD

Leon Berard Center

Recruiting

Lyon,69373,France

Mehdi Brahmi

Bergonie Institute

Recruiting

Bordeaux,33000,France

Antoine Italiano

Gruppo Humanitas - Humanitas Research Hospital - Cancer Center

Recruiting

Milan,20089,Italy

Carmelo Carlo-Stella

University Polyclinic Foundation "Agostino Gemelli" - IRCCS

Recruiting

Rome,00168,Italy

Vanda Salutari

National Cancer Institute, IRCCS

Recruiting

Milan,20133,Italy

Fedelica Mogavero
Mara Mantiero

European Institute of Oncology (IEO), IRCCS

Recruiting

Milan,20141,Italy

Beatrice Rizzoli
Nicoleta Colombo

Irccs University Hospital of Bologna

Recruiting

Bologna,40138,Italy

Pier Luigi Zinzani, MD
Silvia Corazza

Asan Medical Center

Recruiting

Seoul,05505,Korea, Republic of

Hur Soo Yung
Lee Jin Hwa

Gachon University Gil Medical Center

Recruiting

Incheon,21565,Korea, Republic of

Lee Kwang-Beom
Yoon Jiae

Gangnam Severance Hospital

Recruiting

Seoul,Korea, Republic of

Jae-Hoon Kim
Mina Jang

Seoul National University Hospital

Recruiting

Seoul,03080,Korea, Republic of

Kim Jae-Weon
Kim So Jeong

Keimyung University - Dongsan Medical Center

Recruiting

Daegu,42601,Korea, Republic of

Chi Chi-Heum
Cho SeHee

Severance Hospital, Yonsei University Health System

Recruiting

Seoul,03722,Korea, Republic of

Lee Jihyun
Lee Jung-Yun

National Cancer Center

Recruiting

Gyeonggi-do,10408,Korea, Republic of

Heo Suyeon
Lim Myong Cheol

Polish Mother's Memorial Hospital-Research Institute

Recruiting

Lodz,Poland

Jan Walewski, MD
Marta Grubiak
Hubert Kondarewicz
Marek Kotlarski, MD
Anna Pich
Ewa Kalinka

University Teaching Hospital in Poznan, Department of Gynecologic Oncology

Recruiting

Poznan,60-569,Poland

Krzysztof Balcerzak
Radoslaw Madry

University Teaching Centre, Early Clinical Trials Unit

Recruiting

Gdansk,80-214,Poland

Rafal Dziadziuszko
Zofia Specht-Szwoch

University Hospital Vall d'Hebron

Recruiting

Barcelona,Spain

Maria Aleman Ramos
Ana Oaknin
Alejandro Falcon Gonzalez
Valentina Boni
Maria Pilar Barretina Ginesta
Montserrat Dominguez
Jesus Alarcon
Nuria Martin
Antonio Gonzalez Martin
Carolina Garcia Martinez
Ignacio Romero Noguera
Neomi Ceron Pisa
Irene Pascual
Lidia Riquelme
Teresa Curiel Garcia
Ana Landa Magdalena
Luis Manso Sanchez
Alba Meire
Mercedes Egana Gorraiz
Albert Meire (Oncology)

University Clinical Hospital of Salamanca

Recruiting

Salamanca,Castilla Y Leon,37007,Spain

Manuel Delgado Criado
Martin Garcia-Sancho, MD, PhD

Royal United Hospital

Recruiting

Bath,United Kingdom

Emma Cattell
Harriet Walter, MD
Tamlyn Russel
Sarah Porter
Fiona Williams
Rebecca Bowen
Susana Banerjee
Samantha Curtis

Imperial College Healthcare NHS Trust

Recruiting

London,Sw7 2az,United Kingdom

Jonathan Krell
Lauren Holt

Dana Farber Cancer Institute

Recruiting

Boston,Massachusetts,02215,United States

Brian Rasp
Alok Tewari, MD

Swedish Cancer Institute

Recruiting

Seattle,Washington,98104,United States

Charles Drescher, MD
Chun-Fang Qiu

Winship Cancer Institute of Emory University

Recruiting

Atlanta,Georgia,30322,United States

R. Donald Harvey, MD
Adam Burgess

NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center

Recruiting

New York,New York,10016,United States

Stephen Cumberbatch
Salman Punekar, MD

South Texas Accelerated Research Therapeutics (Start) - Midwest Location

Recruiting

Grand Rapids,Michigan,49546,United States

Nehal Lakhani, MD
Oliva Sweeney
Yvette Cole

University of Chicago Medical Center

Recruiting

Chicago,Illinois,60637,United States

Hedy Kindler, MD
Iryna Kobrynets

South Texas Accelerated Research Therapeutics

Recruiting

San Antonio,Texas,78229,United States

Carrie Choi, RN
Drew Rasco, MD
Karen Mcgee

Fred Hutchinson Cancer

Recruiting

Seattle,Washington,98109-1023,United States

Elizabeth Liu
Kalyan Banda, MD

Massachusetts General Hospital

Recruiting

Boston,Massachusetts,02114,United States

Ryan Sullivan, MD
Terry Liu

Hackensack University Medical Center

Recruiting

Hackensack,New Jersey,07601,United States

Celina Joco
Martin Gutierrez, MD

University of Virginia Health System

Recruiting

Charlottesville,Virginia,22903,United States

Chrystal Axford
Linda Duska, MD

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Medical Information


Source URL: https://prod1.novartis.com/clinicaltrials/study/nct04104776

List of links present in page
  1. https://clinicaltrials.gov/ct2/show/NCT04104776
  2. #trial-eligibility
  3. tel:+33 (0) 3 20 29 56 38
  4. mailto:s-chalal@o-lambret.fr
  5. tel:+33 (0) 240 08 40 30
  6. mailto:tiphaine.chiron@chu-nantes.fr
  7. tel:+33 (0) 2 53 48 22 43
  8. mailto:claire.peluchon@chu-nantes.fr
  9. tel:+33 (0) 2 40 16 56 98
  10. mailto:helene.godet@chu-nantes.fr
  11. tel:+33 (0) 368767150
  12. mailto:a.casper@icans.eu
  13. tel:+33 (0) 142 11 61 72
  14. mailto:Mariem.LABIADH@gustaveroussy.fr
  15. tel:+33 (0) 4 78 78 20 62
  16. mailto:emilie.repetto@lyon.unicancer.fr
  17. tel:+33 (556) 333-282
  18. mailto:l.wanner@bordeaux.unicancer.fr
  19. tel:39 02 8224 5954
  20. mailto:laura.paladini@cancercenter.humanitas.it
  21. tel:+39 (06) 30158 545
  22. mailto:giulia.ferrera@policlinicogemelli.it
  23. mailto:Federica.Mogavero@istitutotumori.mi.it
  24. tel:+39 (029) 4372-183
  25. mailto:Beatrice.Rizzoli@ieo.it
  26. tel:39 051 214 3231
  27. mailto:silvia.corazza3@unibo.it
  28. tel:82-22-045-3855
  29. mailto:ljh3531@amc.seoul.kr
  30. tel:010-7583-3119
  31. mailto:76344@ncc.re.kr
  32. tel:8210-8737-0811
  33. mailto:mnj2023sc@yuhs.ac
  34. tel:010-9266-2851
  35. mailto:snu_sojeong@snu.ac.kr
  36. tel:82 (53) 258 6679
  37. mailto:cjjs200400@gmail.com
  38. tel:82 22-228-2759
  39. mailto:HMJH24@yuhs.ac
  40. tel:82-31-920-0859
  41. mailto:76656@ncc.re.kr
  42. tel:0048 792 206 646
  43. mailto:grubiak.marta@gmail.com
  44. tel:0048 512 491 461
  45. mailto:hubert.kondarewicz@pratia.com
  46. tel:0048 22 546 2223
  47. mailto:Anna.Pich@nio.gov.pl
  48. tel:0048 574432284
  49. mailto:kbalcerzak@ump.edu.pl
  50. tel:48 58 584 44 17
  51. mailto:zspecht@uck.gda.pl
  52. tel:+34 (91) 353 1920 Ext 7539
  53. mailto:maleman@unav.es
  54. tel:+34 914521900 (ext. 38901)
  55. mailto:rsanchez@nextoncology.eu
  56. tel:+34 (696) 635-551
  57. mailto:montse.oncologiahuvr@gmail.com
  58. tel:+34 972 75 49 53
  59. mailto:nmartin@iconcologia.net
  60. tel:+34981950512/ +3498195567
  61. mailto:cgarciamartinez.enf@gmail.com
  62. tel:+34 871 20 61 30
  63. mailto:noemi.ceron@ssib.es
  64. tel:+34 913908626
  65. mailto:ipascualsr.imas12@h12o.es
  66. tel:+34 663224865
  67. mailto:datamanager3@fincivo.org
  68. tel:(+34)93 274 60 00 4691
  69. mailto:ameire@vhio.net
  70. tel:+34 (948) 255 400 Ext 2733
  71. mailto:megana@unav.es
  72. tel:+34 93 274 60 00
  73. mailto:ameire@vhio.net
  74. tel:+34 (923) 291 316
  75. mailto:mdelgadocri@saludcastillayleon.es
  76. tel:01823 342582
  77. mailto:Tamlyn.Russell@SomersetFT.nhs.uk
  78. tel:0116 258 7598
  79. mailto:sarah.porter@uhl-tr.nhs.uk
  80. tel:442031865362
  81. mailto:Fiona.Williams@rmh.nhs.uk
  82. tel:01225 824288
  83. mailto:samantha.curtis@nhs.net
  84. tel:0208 383 1366
  85. mailto:lauren.holt9@nhs.net
  86. tel:857-215-2265
  87. mailto:Brian_Rasp@DFCI.Harvard.edu
  88. tel:206-215-6430
  89. mailto:Chun-fang.Qiu@swedish.org
  90. tel:404-712-9858
  91. mailto:adam.burgess@emory.edu
  92. tel:407-517-8471
  93. mailto:Stephen.Cumberbatch@nyulangone.org
  94. tel:616-954-5554
  95. mailto:olivia.sweeney@startmidwest.com
  96. tel:616-954-5554
  97. mailto:Yvette.Cole@startmidwest.com
  98. tel:773-834-6421
  99. mailto:Iryna.Kobrynets@bsd.uchicago.edu
  100. tel:210-593-2547
  101. mailto:carrie.choi@startsa.com
  102. tel:210-593-5270
  103. mailto:karen.mcgee@startsa.com
  104. tel:206-606-7494
  105. mailto:elizliu@seattlecca.org
  106. tel:617-632-9250
  107. mailto:TLIU32@mgh.harvard.edu
  108. tel:551-996-8170
  109. mailto:Celina.Joco@hmhn.org
  110. tel:804-683-2880
  111. mailto:Cgp9e@hscmail.mcc.virginia.edu
  112. tel:(844) 667-1992
  113. mailto:medinfo@morphosys.com